1887

Chapter 12 : Shiga Toxin-Producing

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Shiga Toxin-Producing , Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817114/9781555819354_Chap12-1.gif /docserver/preview/fulltext/10.1128/9781555817114/9781555819354_Chap12-2.gif

Abstract:

This chapter discusses the emergence and impact of shiga toxin-producing (STEC) in human disease, the biology of the Shiga toxins (Stx) family, and approaches to diagnosis, treatment, and prevention of infection with STEC. The occurrence of the seminal STEC outbreaks highlighted the need to implement laboratory methods to readily detect O157:H7. Although early characterization of STEC strains was made possible by Whittam’s multilocus enzyme electrophoresis (MLEE) method, genetic techniques now allow comparison of strains at the nucleotide level. The current model of the predominant pathway by which Stx intoxicates sensitive cells is as follows: (i) the B pentamer of holotoxin binds to Gb within lipid rafts; (ii) the entire receptor-holotoxin complex is endocytosed; (iii) the complex moves by retrograde transport to the Golgi and then to the endoplasmic reticulum; and (iv) the A subunit is released into the cytoplasm, where it targets the ribosome. Although transduction of stx genes into via bacteriophages was crucial to the emergence of STEC, the biology of these toxin-converting phages also contributes significantly to the degree of toxin expression and hence the virulence exhibited by STEC. Although the pathogenicity of various STEC strains that synthesize different types of Stx2 cannot be compared directly because the strains are not isogenic, the authors have found that an O91 strain that produces Stx2 is not virulent in the streptomycin-treated mouse model for STEC infection, whereas O91 strains that produce Stx2d-activatable are highly virulent in those mice.

Citation: Teel L, Melton-Celsa A, O’Brien A. 2011. Shiga Toxin-Producing , p 199-223. In Walk S, Feng P (ed), Population Genetics of Bacteria. ASM Press, Washington, DC. doi: 10.1128/9781555817114.ch12

Key Concept Ranking

Type III Secretion System
0.47071618
Type II Secretion System
0.4516974
Restriction Fragment Length Polymorphism
0.4469427
0.47071618
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

Ribbon diagram of the Stx2 crystal structure. The A subunit is depicted in black while the five B subunits are shown in alternating light and dark gray. This image (Protein Data Bank ID: 1R4P) was generated with Protein Workshop 3.6.

Citation: Teel L, Melton-Celsa A, O’Brien A. 2011. Shiga Toxin-Producing , p 199-223. In Walk S, Feng P (ed), Population Genetics of Bacteria. ASM Press, Washington, DC. doi: 10.1128/9781555817114.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Stx expression is under the control of multiple genetic elements. Expression of and the lambdoid late genes is repressed during lysogeny by the binding of the phage repressor CI to sites between the early left and right promoter regions ( and ). Upon phage induction, the CI repressor is cleaved and the N antiterminator is transcribed from . N facilitates transcription through numerous terminator sequences ( ), such that the Q antiterminator is expressed. When Q binds , the ′ promoter is active and transcription proceeds through the operon and on through the (holin) and (endolysin) genes further downstream. Thus Q antitermination and transcription originating at ′ contributes most strongly to Stx1 and Stx2 production upon phage induction. Stx1 expression is also partially mediated by an iron-repressed (Fur) promoter, . Very low levels of Stx1 are produced when the bacteria are grown in high iron conditions in the absence of phage induction, and in low iron conditions Stx1 expression from the promoter is enhanced. Low levels of transcription originating at occur in the absence of phage induction independent of iron concentration. Arrows denote the length of transcripts with and without antitermination. The relative strength of each promoter is indicated by the thickness of the transcript arrows. Based on diagrams by Wagner et al. ( ) and reprinted with permission of the publisher.

Citation: Teel L, Melton-Celsa A, O’Brien A. 2011. Shiga Toxin-Producing , p 199-223. In Walk S, Feng P (ed), Population Genetics of Bacteria. ASM Press, Washington, DC. doi: 10.1128/9781555817114.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817114.ch12
1. Ahmed, A.,, J. Li,, Y. Shiloach,, J. B. Robbins, and, S. C. Szu. 2006. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2–5-year-old children. J. Infect. Dis. 193:515521.
2. Ahn, C. K.,, E. Klein, and, P. I. Tarr. 2008. Isolation of patients acutely infected with Escherichia coli O157:H7: low-tech, highly effective prevention of hemolytic uremic syndrome. Clin. Infect. Dis. 46:11971199.
3. Ake, J. A.,, S. Jelacic,, M. A. Ciol,, S. L. Watkins,, K. F. Murray,, D. L. Christie,, E. J. Klein,, and P. I. Tarr. 2005. Relative nephroprotection during Escherichia coli O157: H7 infections: association with intravenous volume expansion. Pediatrics 115:e673e680.
4. Allen, K. P.,, M. M. Randolph, and, J. M. Fleckenstein. 2006. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. Infect. Immun. 74:869875.
5. Armstrong, G. D.,, G. L. Mulvey,, P. Marcato,, T. P. Griener,, M. C. Kahan,, G. A. Tennent,, C. A. Sabin,, H. Chart, and, M. B. Pepys. 2006. Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic uremic syndrome. J. Infect. Dis. 193:11201124.
6. Asadulghani, M.,, Y. Ogura,, T. Ooka,, T. Itoh,, A. Sawaguchi,, A. Iguchi,, K. Nakayama, and, T. Hayashi. 2009. The defective prophage pool of Escherichia coli O157: prophage-prophage interactions potentiate horizontal transfer of virulence determinants. PLoS Pathog. 5:e1000408.
7. Besser, R. E.,, S. M. Lett,, J. T. Weber,, M. P. Doyle,, T. J. Barrett,, J. G. Wells, and, P. M. Griffin. 1993. An outbreak of diarrhea and hemolytic uremic syndrome from Escherichia coli O157:H7 in fresh-pressed apple cider. JAMA 269:22172220.
8. Bettelheim, K. A. 2003. Non-O157 verotoxin-producing Escherichia coli: a problem, paradox, and paradigm. Exp. Biol. Med. (Maywood) 228:333344.
9. Beutin, L.,, A. Miko,, G. Krause,, K. Pries,, S. Haby,, K. Steege, and, N. Albrecht. 2007. Identification of human-pathogenic strains of Shiga toxin-producing Escherichia coli from food by a combination of serotyping and molecular typing of Shiga toxin genes. Appl. Environ. Microbiol. 73:47694775.
10. Beutin, L.,, M. A. Montenegro,, I. Ørskov,, F. Ørskov,, J. Prada,, S. Zimmermann, and, R. Stephan. 1989. Close association of verotoxin (Shiga-like toxin) production with enterohemolysin production in strains of Escherichia coli. J. Clin. Microbiol. 27:25592564.
11. Beutin, L.,, S. Zimmermann, and, K. Gleier. 1998. Human infections with Shiga toxin-producing Escherichia coli other than serogroup O157 in Germany. Emerg. Infect. Dis. 4:635639.
12. Bielaszewska, M. 2009. Detection of STEC/VTEC in human samples, abstr. S07.1. In Abstracts of the 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina.
13. Bielaszewska, M.,, A. W. Friedrich,, T. Aldick,, R. Schurk-Bulgrin, and, H. Karch. 2006. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin. Infect. Dis. 43:11601167.
14. Bitzan, M. 2009. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int. 75:S62S66.
15. Boyce, T. G.,, A. G. Pemberton,, J. G. Wells, and, P. M. Griffin. 1995. Screening for Escherichia coli O157:H7—a nationwide survey of clinical laboratories. J. Clin. Microbiol. 33:32753277.
16. Brooks, J. T.,, E. G. Sowers,, J. G. Wells,, K. D. Greene,, P. M. Griffin,, R. M. Hoekstra, and, N. A. Strockbine. 2005. Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983–2002. J. Infect. Dis. 192:14221429.
17. Calderwood, S. B.,, and J. J. Mekalanos. 1987. Iron regulation of Shiga-like toxin expression in Escherichia coli is mediated by the fur locus. J. Bacteriol. 169:47594764.
18. Centers for Disease Control and Prevention. 1999. Outbreak of Escherichia coli O157: H7 and Campylobacter among attendees of the Washington County Fair—New York, 1999. MMWR Morb. Mortal. Wkly. Rep. 48:803805.
19. Centers for Disease Control and Prevention. 2002. Multistate outbreak of Escherichia coli O157:H7 infections associated with eating ground beef—United States, June–July 2002. MMWR Morb. Mortal. Wkly. Rep. 51:637639.
20. Centers for Disease Control and Prevention. 2007. Laboratory-confirmed non-O157 Shiga toxin-producing Escherichia coli—Connecticut, 2000–2005. MMWR Morb. Mortal. Wkly. Rep. 56:2931.
21. Centers for Disease Control and Prevention. 1995. Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:H21—Helena, Montana, 1994. MMWR Morb. Mortal. Wkly. Rep. 44:501503.
22. Church, D. L.,, D. Emshey,, H. Semeniuk,, T. Lloyd, and, J. D. Pitout. 2007. Evaluation of BBL CHROMagar O157 versus sorbitol-MacConkey medium for routine detection of Escherichia coli O157 in a centralized regional clinical microbiology laboratory. J. Clin. Microbiol. 45:30983100.
23. Dowling, T. C.,, P. A. Chavaillaz,, D. G. Young,, A. Melton-Celsa,, A. O’Brien,, C. Thuning-Roberson,, R. Edelman, and, C. O. Tacket. 2005. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody cαStx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother. 49:18081812.
24. Edwards, A. C.,, A. R. Melton-Celsa,, K. Arbuthnott,, J. R. Stinson,, C. K. Schmitt,, H. C. Wong, and, A. D. O’Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388–392. In J. B. Kaper and, A. D. O’Brien (ed.), Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. ASM Press, Washington, DC.
25. Farmer, J. J., III,, and B. R. Davis. 1985. H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. J. Clin. Microbiol. 22:620625.
26. Feng, P.,, K. A. Lampel,, H. Karch, and, T. S. Whittam. 1998. Genotypic and phenotypic changes in the emergence of Escherichia coli O157:H7. J. Infect. Dis. 177:17501753.
27. Fox, J. T.,, D. U. Thomson,, J. S. Drouillard,, A. B. Thornton,, D. T. Burkhardt,, D. A. Emery, and, T. G. Nagaraja. 2009. Efficacy of Escherichia coli O157:H7 siderophore receptor/porin proteins-based vaccine in feedlot cattle naturally shedding E. coli O157. Foodborne Pathog. Dis. 6:893899.
28. Fraser, M. E.,, M. M. Chernaia,, Y. V. Kozlov, and, M. N. James. 1994. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1:5964.
29. Fraser, M. E.,, M. Fujinaga,, M. M. Cherney,, A. R. Melton-Celsa,, E. M. Twiddy,, A. D. O’Brien, and, M. N. James. 2004. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 279:2751127517.
30. Fuchs, S.,, I. Muhldorfer,, A. Donohue-Rolfe,, M. Kerenyi,, L. Emody,, R. Alexiev,, P. Nenkov, and, J. Hacker. 1999. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb. Pathog. 27:1323.
31. Fujii, J.,, T. Kita,, S. Yoshida,, T. Takeda,, H. Kobayashi,, N. Tanaka,, K. Ohsato, and, Y. Mizuguchi. 1994. Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H in mitomycin-treated mice. Infect. Immun. 62:34473453.
32. Gauthier, A.,, and B. B. Finlay. 2003. Translocated intimin receptor and its chaperone interact with ATPase of the type III secretion apparatus of enteropathogenic Escherichia coli. J. Bacteriol. 185:67476755.
33. Gerber, A.,, H. Karch,, F. Allerberger,, H. M. Verweyen, and, L. B. Zimmerhackl. 2002. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J. Infect. Dis. 186:493500.
34. Goldwater, P. N. 2007. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome. Expert Rev. Anti Infect. Ther. 5:653663.
35. Gould, L. H.,, C. Bopp,, N. Strockbine,, R. Atkinson,, V. Baselski,, B. Body,, R. Carey,, C. Crandall,, S. Hurd,, R. Kaplan,, M. Neill,, S. Shea,, P. Somsel,, M. Tobin-D’Angelo,, P. M. Griffin, and, P. Gerner-Smidt. 2009. Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm. Rep. 58:114.
36. Gould, L. H.,, M. M. Leeper,, D. MacCannell,, P. M. Griffin, and, P. Gerner-Smidt. 2009. Trends in toxin profiles of human Shiga toxin-producing Escherichia coli (STEC) O157 Strains, United States, 1996–2008, abstr. P02.4.9. In Abstracts of the 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina.
37. Griffin, P. M. 1995. Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli, p. 739–761. In M. J. Blaser,, P. D. Smith,, J. I. Ravdin,, H. B. Greenberg, and, R. L. Guerrant (ed.), Infections of the Gastrointestinal Tract. Raven Press, New York, NY.
38. Griffin, P. M. 1998. Epidemiology of Shiga toxin-producing Escherichia coli infections in humans in the United States, p. 15–22. In J. B. Kaper and, A. D. O’Brien (ed.), Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. ASM Press, Washington, DC.
39. Griffin, P. M.,, L. H. Gould,, T. Ayers, and, M. M. Leeper. 2009. Epidemiology of Shiga toxin-producing Escherichia coli (STEC) infections in the United States, abstr. S02.2. In Abstracts of the 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina.
40. Grys, T. E.,, M. B. Siegel,, W. W. Lathem, and, R. A. Welch. 2005. The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect. Immun. 73:12951303.
41. Herold, S.,, J. C. Paton, and, A. W. Paton. 2009. Sab, a novel autotransporter of locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli O113:H21, contributes to adherence and biofilm formation. Infect. Immun. 77:32343243.
42. Hilborn, E. D.,, J. H. Mermin,, P. A. Mshar,, J. L. Hadler,, A. Voetsch,, C. Wojtkunski,, M. Swartz,, R. Mshar,, M. A. Lambert-Fair,, J. A. Farrar,, M. K. Glynn, and, L. Slutsker. 1999. A multistate outbreak of Escherichia coli O157:H7 infections associated with consumption of mesclun lettuce. Arch. Intern. Med. 159:17581764.
43. Hu, J.,, D. Green,, J. Swoveland,, M. Grant, and, D. S. Boyle. 2009. Preliminary evaluation of a procedure for improved detection of Shiga toxin-producing Escherichia coli in fecal specimens. Diagn. Microbiol. Infect. Dis. 65:2126.
44. Ikeda, K.,, O. Ida,, K. Kimoto,, T. Takatorige,, N. Nakanishi, and, K. Tatara. 1999. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin. Nephrol. 52:357362.
45. Jelacic, J. K.,, T. Damrow,, G. S. Chen,, S. Jelacic,, M. Bielaszewska,, M. Ciol,, H. M. Carvalho,, A. R. Melton-Celsa,, A. D. O’Brien, and, P. I. Tarr. 2003. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J. Infect. Dis. 188:719729.
46. Johannes, L.,, and W. Römer. 2010. Shiga toxins—from cell biology to biomedical applications. Nat. Rev. Microbiol. 8:105116.
47. Johansen, B. K.,, Y. Wasteson,, P. E. Granum, and, S. Brynestad. 2001. Mosaic structure of Shiga-toxin-2-encoding phages isolated from Escherichia coli O157:H7 indicates frequent gene exchange between lambdoid phage genomes. Microbiology 147:19291936.
48. Johnson, K. E.,, C. M. Thorpe, and, C. L. Sears. 2006. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin. Infect. Dis. 43:15871595.
49. Judge, N. A.,, H. S. Mason, and, A. D. O’Brien. 2004. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect. Immun. 72:168175.
50. Kaper, J. B.,, S. Elliott,, V. Sperandio,, N. T. Perna,, G. F. Mayhew, and, F. R. Blattner. 1998. Attaching-and-effacing intestinal histopathology and the locus of enterocyte effacement, p. 163–182. In J. B. Kaper and, A. D. O’Brien (ed.), Escherichia coli O157: H7 and Other Shiga Toxin-Producing E. coli Strains. ASM Press, Washington, DC.
51. Kaper, J. B.,, J. P. Nataro, and, H. L. T. Mobley. 2004. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2:123140.
52. Kim, Y. B.,, J. Okuda,, C. Matsumoto,, T. Morigaki,, N. Asai,, H. Watanabe, and, M. Nishibuchi. 1998. Isolation of an Escherichia coli O157:H7 strain producing Shiga toxin 1 but not Shiga toxin 2 from a patient with hemolytic uremic syndrome in Korea. FEMS Microbiol. Lett. 166:4348.
53. Kimura, T.,, S. Tani,, Y. Y. Matsumoto, and, T. Takeda. 2001. Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J. Biol. Chem. 276:4157641579.
54. Kimura, T.,, S. Tani,, M. Motoki, and, Y. Matsumoto. 2003. Role of Shiga toxin 2 (Stx2)-binding protein, human serum amyloid P component (HuSAP), in Shiga toxin-producing Escherichia coli infections: assumption from in vitro and in vivo study using HuSAP and anti-Stx2 humanized monoclonal antibody TMA-15. Biochem. Biophys. Res. Commun. 305:10571060.
55. Klein, E. J.,, J. R. Stapp,, C. R. Clausen,, D. R. Boster,, J. G. Wells,, X. Qin,, D. L. Swerdlow, and, P. I. Tarr. 2002. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J. Pediatr. 141:172177.
56. Klein, E. J.,, J. R. Stapp,, M. A. Neill,, J. M. Besser,, M. T. Osterholm, and, P. I. Tarr. 2004. Shiga toxin antigen detection should not replace sorbitol MacConkey agar screening of stool specimens. J. Clin. Microbiol. 42:44164417.
57. Lainhart, W.,, G. Stolfa, and, G. B. Koudelka. 2009. Shiga toxin as a bacterial defense against a eukaryotic predator, Tetrahymena thermophila. J. Bacteriol. 191:51165122.
58. Lathem, W. W.,, T. E. Grys,, S. E. Witowski,, A. G. Torres,, J. B. Kaper,, P. I. Tarr, and, R. A. Welch. 2002. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol. Microbiol. 45:277288.
59. Levine, M. M.,, J. G. Xu,, J. B. Kaper,, H. Lior,, V. Prado,, B. Tall,, J. Nataro,, H. Karch, and, K. Wachsmuth. 1987. A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J. Infect. Dis. 156:175182.
60. Livny, J.,, and D. I. Friedman. 2004. Characterizing spontaneous induction of Stx encoding phages using a selectable reporter system. Mol. Microbiol. 51:16911704.
61. López, E. L.,, M. M. Contrini,, E. Glatstein,, A. S. González,, R. Santoro,, D. Allende,, G. Ezcurra,, E. Teplitz,, T. Koyama,, Y. Matsumoto,, H. Sato,, K. Sakai,, S. Hoshide,, K. Komoriya,, T. Morita,, R. Harning, and, S. Brookman. 2010. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob. Agents Chemother. 54:239243.
62. Louise, C. B.,, and T. G. Obrig. 1995. Specific interaction of Escherichia coli O157: H7-derived Shiga-like toxin II with human renal endothelial cells. J. Infect. Dis. 172:13971401.
63. Lowe, R. M.,, D. Baines,, L. B. Selinger,, J. E. Thomas,, T. A. McAllister, and, R. Sharma. 2009. Escherichia coli O157:H7 strain origin, lineage, and Shiga toxin 2 expression affect colonization of cattle. Appl. Environ. Microbiol. 75:50745081.
64. Maki, D. G. 2006. Don’t eat the spinach—controlling foodborne infectious disease. N. Engl. J. Med. 355:19521955.
65. Makino, K.,, K. Ishii,, T. Yasunaga,, M. Hattori,, K. Yokoyama,, C. H. Yutsudo,, Y. Kubota,, Y. Yamaichi,, T. Iida,, K. Yamamoto,, T. Honda,, C. G. Han,, E. Ohtsubo,, M. Kasamatsu,, T. Hayashi,, S. Kuhara, and, H. Shinagawa. 1998. Complete nucleotide sequences of 93-kb and 3.3-kb plasmids of an enterohemorrhagic Escherichia coli O157: H7 derived from Sakai outbreak. DNA Res. 5:19.
66. Manning, S. D.,, R. T. Madera,, W. Schneider,, S. E. Dietrich,, W. Khalife,, W. Brown,, T. S. Whittam,, P. Somsel, and, J. T. Rudrik. 2007. Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001–2005. Emerg. Infect. Dis. 13:318321.
67. Manning, S. D.,, A. S. Motiwala,, A. C. Springman,, W. Qi,, D. W. Lacher,, L. M. Ouellette,, J. M. Mladonicky,, P. Somsel,, J. T. Rudrik,, S. E. Dietrich,, W. Zhang,, B. Swaminathan,, D. Alland, and, T. S. Whittam. 2008. Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc. Natl. Acad. Sci. USA 105:48684873.
68. McNeilly, T. N.,, M. C. Mitchell,, T. Rosser,, S. McAteer,, J. C. Low,, D. G. Smith,, J. F. Huntley,, A. Mahajan, and, D. L. Gally. 2010. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine 28:14221428.
69. Melton-Celsa, A. R.,, J. F. Kokai-Kun, and, A. D. O’Brien. 2002. Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer. Mol. Microbiol. 43:207215.
70. Melton-Celsa, A. R.,, and A. D. O’Brien. 2000. Shiga toxins of Shigella dysenteriae and Escherichia coli, p. 385–406. In K. Aktories and, I. Just (ed.), Handbook of Experimental Pharmacology, vol. 145. Springer-Verlag, Berlin, Germany.
71. Melton-Celsa, A. R.,, M. J. Smith, and, A. D. O’Brien. 2005. Shiga toxins: potent poisons, pathogenicity determinants, and pharmacological agents. In R. Curtiss III (ed.), EcoSal: Escherichia coli and Salmonella, Cellular and Molecular Biology, 2nd ed. ASM Press, Washington, DC. [Online.]
72. Moreland, J. L.,, A. Gramada,, O. V. Buzko,, Q. Zhang, and, P. E. Bourne. 2005. The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics 6:21.
73. Mukherjee, J.,, K. Chios,, D. Fishwild,, D. Hudson,, S. O’Donnell,, S. M. Rich,, A. Donohue-Rolfe, and, S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612619.
74. Nishikawa, K.,, M. Watanabe,, E. Kita,, K. Igai,, K. Omata,, M. B. Yaffe, and, Y. Natori. 2006. A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin. FASEB J. 20:25972599.
75. O’Brien, A. D.,, J. W. Newland,, S. F. Miller,, R. K. Holmes,, H. W. Smith, and, S. B. Formal. 1984. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 226:694696.
76. O’Brien, A. D.,, V. L. Tesh,, A. Donohue-Rolfe,, M. P. Jackson,, S. Olsnes,, K. Sandvig,, A. A. Lindberg, and, G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis, p. 66–94. In P. J. Sansonetti (ed.), Pathogenesis of Shigellosis. Springer-Verlag, Berlin, Germany.
77. Ogura, Y.,, T. Ooka,, A. Iguchi,, H. Toh,, M. Asadulghani,, K. Oshima,, T. Kodama,, H. Abe,, K. Nakayama,, K. Kurokawa,, T. Tobe,, M. Hattori, and, T. Hayashi. 2009. Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic Escherichia coli. Proc. Natl. Acad. Sci. USA 106:1793917944.
78. Ohmura-Hoshino, M.,, S. T. Ho,, H. Kurazono,, K. Igarashi,, S. Yamasaki, and, Y. Takeda. 2003. Genetic and immunological analysis of a novel variant of Shiga toxin 1 from bovine Escherichia coli strains and development of bead-ELISA to detect the variant toxin. Microbiol. Immunol. 47:717725.
79. Orth, D.,, K. Grif,, L. B. Zimmerhackl, and, R. Würzner. 2008. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev. Anti Infect. Ther. 6:101108.
80. Ostroff, S. M.,, P. I. Tarr,, M. A. Neill,, J. H. Lewis,, N. Hargrett-Bean, and, J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160:994998.
81. Panos, G. Z.,, G. I. Betsi, and, M. E. Falagas. 2006. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment. Pharmacol. Ther. 24:731742.
82. Paton, A. W.,, T. Beddoe,, C. M. Thorpe,, J. C. Whisstock,, M. C. J. Wilce,, J. Ross-john,, U. M. Talbot, and, J. C. Paton. 2006. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 443:548552.
83. Paton, A. W.,, and J. C. Paton. 2005. Multiplex PCR for direct detection of Shiga toxigenic Escherichia coli strains producing the novel subtilase cytotoxin. J. Clin. Microbiol. 43:29442947.
84. Paton, A. W.,, P. Srimanote,, U. M. Talbot,, H. Wang, and, J. C. Paton. 2004. A new family of potent AB5 cytotoxins produced by Shiga toxigenic Escherichia coli. J. Exp. Med. 200:3546.
85. Paton, A. W.,, P. Srimanote,, M. C. Woodrow, and, J. C. Paton. 2001. Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans. Infect. Immun. 69:69997009.
86. Paton, J. C.,, and A. W. Paton. 2006. Shiga toxin “goes retro” in human primary kidney cells. Kidney Int. 70:20492051.
87. Pinyon, R. A.,, J. C. Paton,, A. W. Paton,, J. A. Botten, and, R. Morona. 2004. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J. Infect. Dis. 189:15471555.
88. Potter, A. A.,, S. Klashinsky,, Y. Li,, E. Frey,, H. Townsend,, D. Rogan,, G. Erickson,, S. Hinkley,, T. Klopfenstein,, R. A. Moxley,, D. R. Smith, and, B. B. Finlay. 2004. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22:362369.
89. Ptashne, M. 2004. A Genetic Switch, 3rd ed., p. 5261. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
90. Rangel, J. M.,, P. H. Sparling,, C. Crowe,, P. M. Griffin, and, D. L. Swerdlow. 2005. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982–2002. Emerg. Infect. Dis. 11:603609.
91. Repetto, H. A. 2009. Overview of HUS in Argentina, abstr. S01.1. In Abstracts of the 7th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections. Buenos Aires, Argentina.
92. Ribot, E. M.,, M. A. Fair,, R. Gautom,, D. N. Cameron,, S. B. Hunter,, B. Swaminathan, and, T. J. Barrett. 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog. Dis. 3:5967.
93. Riley, L. W.,, R. S. Remis,, S. D. Helgerson,, H. B. McGee,, J. G. Wells,, B. R. Davis,, R. J. Hebert,, E. S. Olcott,, L. M. Johnson,, N. T. Hargrett,, P. A. Blake, and, M. L. Cohen. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681685.
94. Robins-Browne, R. M.,, E. Elliott, and, P. Desmarchelier. 1998. Shiga toxin-producing Escherichia coli in Australia, p. 66–72. In J. B. Kaper and, A. D. O’Brien (ed.), Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. ASM Press, Washington, DC.
95. Robinson, C. M.,, J. F. Sinclair,, M. J. Smith, and, A. D. O’Brien. 2006. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. USA 103:96679672.
96. Rogers, T. J.,, and J. C. Paton. 2009. Therapeutic strategies for Shiga toxin-producing Escherichia coli infections. Expert Rev. Anti Infect. Ther. 7:683686.
97. Sandvig, K. 2001. Shiga toxins. Toxicon 39:16291635.
98. Sandvig, K.,, O. Garred,, K. Prydz,, J. V. Kozlov,, S. H. Hansen, and, B. van Deurs. 1992. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358:510512.
99. Sargeant, J. M.,, M. R. Amezcua,, A. Rajic, and, L. Waddell. 2007. Pre-harvest interventions to reduce the shedding of E. coli O157 in the faeces of weaned domestic ruminants: a systematic review. Zoonoses Public Health 54:260277.
100. Scheiring, J.,, S. P. Andreoli, and, L. B. Zimmerhackl. 2008. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr. Nephrol. 23:17491760.
101. Schuetz, F. 1997. Ph.D thesis. Statens Serum Institut, Copenhagen, Denmark.
102. Scotland, S. M.,, G. A. Willshaw,, H. R. Smith, and, B. Rowe. 1987. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 99:613624.
103. Serna, A.,, and E. C. Boedeker. 2008. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr. Opin. Gastroenterol. 24:3847.
104. Seto, E. Y.,, J. A. Soller, and, J. M. Colford, Jr. 2007. Strategies to reduce person-to-person transmission during widespread Escherichia coli O157:H7 outbreak. Emerg. Infect. Dis. 13:860866.
105. Sheng, H.,, J. Y. Lim,, H. J. Knecht,, J. Li, and, C. J. Hovde. 2006. Role of Escherichia coli O157:H7 virulence factors in colonization at the bovine terminal rectal mucosa. Infect. Immun. 74:46854693.
106. Shiomi, M.,, M. Togawa,, K. Fujita, and, R. Murata. 1999. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr. Int. 41:228232.
107. Smith, D. R.,, R. A. Moxley,, R. E. Peterson,, T. J. Klopfenstein,, G. E. Erickson,, G. Bretschneider,, E. M. Berberov, and, S. Clowser. 2009. A two-dose regimen of a vaccine against type III secreted proteins reduced Escherichia coli O157:H7 colonization of the terminal rectum in beef cattle in commercial feedlots. Foodborne Pathog. Dis. 6:155161.
108. Smith, H. W.,, and M. A. Linggood. 1971. The transmissible nature of enterotoxin production in a human enteropathogenic strain of Escherichia coli. J. Med. Microbiol. 4:301305.
109. Smith, M. J.,, L. D. Teel,, H. M. Carvalho,, A. R. Melton-Celsa, and, A. D. O’Brien. 2006. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24:41224129.
110. Snedeker, K. G.,, D. J. Shaw,, M. E. Locking, and, R. J. Prescott. 2009. Primary and secondary cases in Escherichia coli O157 outbreaks: a statistical analysis. BMC Infect. Dis. 9:144.
111. Sung, L. M.,, M. P. Jackson,, A. D. O’Brien, and, R. K. Holmes. 1990. Transcription of the Shiga-like toxin type II and Shiga-like toxin type II variant operons of Escherichia coli. J. Bacteriol. 172:63866395.
112. Teel, L. D.,, A. R. Melton-Celsa,, C. K. Schmitt, and, A. D. O’Brien. 2002. One of two copies of the gene for the activatable Shiga toxin type 2d in Escherichia coli O91: H21 strain B2F1 is associated with an inducible bacteriophage. Infect. Immun. 70:42824291.
113. Tesh, V. L. 2010. Induction of apoptosis by Shiga toxins. Future Microbiol. 5:431453.
114. Thomson, D. U.,, G. H. Loneragan,, A. B. Thornton,, K. F. Lechtenberg,, D. A. Emery,, D. T. Burkhardt, and, T. G. Nagaraja. 2009. Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle. Foodborne Pathog. Dis. 6:871877.
115. Tilden, J., Jr.,, W. Young,, A. M. McNamara,, C. Custer,, B. Boesel,, M. A. Lambert-Fair,, J. Majkowski,, D. Vugia,, S. B. Werner,, J. Hollingsworth, and, J. G. Morris, Jr. 1996. A new route of transmission for Escherichia coli: infection from dry fermented salami. Am. J. Public Health 86:11421145.
116. Trachtman, H.,, A. Cnaan,, E. Christen,, K. Gibbs,, S. Zhao,, D. W. Acheson,, R. Weiss,, F. J. Kaskel,, A. Spitzer, and, G. H. Hirschman. 2003. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:13371344.
117. Tyler, J. S.,, M. J. Mills, and, D. I. Friedman. 2004. The operator and early promoter region of the Shiga toxin type 2-encoding bacteriophage 933W and control of toxin expression. J. Bacteriol. 186:76707679.
118. Tzipori, S.,, H. Karch,, K. I. Wachsmuth,, R. M. Robins-Browne,, A. D. O’Brien,, H. Lior,, M. L. Cohen,, J. Smithers, and, M. M. Levine. 1987. Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect. Immun. 55:31173125.
119. Tzipori, S.,, A. Sheoran,, D. Akiyoshi,, A. Donohue-Rolfe, and, H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926941.
120. Unkmeir, A.,, and H. Schmidt. 2000. Structural analysis of phage-borne stx genes and their flanking sequences in Shiga toxin-producing Escherichia coli and Shigella dysenteriae type 1 strains. Infect. Immun. 68:48564864.
121. Voetsch, A. C.,, F. J. Angulo,, T. Rabatsky-Ehr,, S. Shallow,, M. Cassidy,, S. M. Thomas,, E. Swanson,, S. M. Zansky,, M. A. Hawkins,, T. F. Jones,, P. J. Shillam,, T. J. Van Gilder,, J. G. Wells, and, P. M. Griffin. 2004. Laboratory practices for stool-specimen culture for bacterial pathogens, including Escherichia coli O157:H7, in the FoodNet sites, 1995–2000. Clin. Infect. Dis. 38(Suppl. 3):S190S197.
122. Wadolkowski, E. A.,, L. M. Sung,, J. A. Burris,, J. E. Samuel, and, A. D. O’Brien. 1990. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect. Immun. 58:39593965.
123. Wagner, P. L.,, D. W. Acheson, and, M. K. Waldor. 1999. Isogenic lysogens of diverse Shiga toxin 2-encoding bacteriophages produce markedly different amounts of Shiga toxin. Infect. Immun. 67:67106714.
124. Wagner, P. L.,, J. Livny,, M. N. Neely,, D. W. Acheson,, D. I. Friedman, and, M. K. Waldor. 2002. Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli. Mol. Microbiol. 44:957970.
125. Wagner, P. L.,, M. N. Neely,, X. Zhang,, D. W. Acheson,, M. K. Waldor, and, D. I. Friedman. 2001. Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J. Bacteriol. 183:20812085.
126. Wang, I. N.,, D. L. Smith, and, R. Young. 2000. Holins: the protein clocks of bacteriophage infections. Annu. Rev. Microbiol. 54:799825.
127. Watanabe-Takahashi, M.,, T. Sato,, T. Dohi,, N. Noguchi,, F. Kano,, M. Murata,, T. Hamabata,, Y. Natori, and, K. Nishikawa. 2010. An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect. Immun. 78:177183.
128. Werber, D.,, B. W. Mason,, M. R. Evans, and, R. L. Salmon. 2008. Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin. Infect. Dis. 46:11891196.
129. Whittam, T. S. 1998. Evolution of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains, p. 195–209. In J. B. Kaper and, A. D. O’Brien (ed.), Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains. ASM Press, Washington, DC.
130. Whittam, T. S.,, I. K. Wachsmuth, and, R. A. Wilson. 1988. Genetic evidence of clonal descent of Escherichia coli O157:H7 associated with hemorrhagic colitis and hemolytic uremic syndrome. J. Infect. Dis. 157:11241133.
131. Whittam, T. S.,, M. L. Wolfe,, I. K. Wachsmuth,, F. Ørskov,, I. Ørskov, and, R. A. Wilson. 1993. Clonal relationships among Escherichia coli strains that cause hemorrhagic colitis and infantile diarrhea. Infect. Immun. 61:16191629.
132. Wong, C. S.,, S. Jelacic,, R. L. Habeeb,, S. L. Watkins, and, P. I. Tarr. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N. Engl. J. Med. 342:19301936.
133. Yamagami, S.,, M. Motoki,, T. Kimura,, H. Izumi,, T. Takeda,, Y. Katsuura, and, Y. Matsumoto. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738742.
134. Zhang, Q.,, A. Donohue-Rolfe,, G. Krautz-Peterson,, M. Sevo,, N. Parry,, C. Abeijon, and, S. Tzipori. 2009. Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J. Infect. Dis. 199:486493.
135. Zhang, W. L.,, M. Bielaszewska,, A. Liesegang,, H. Tschäpe,, H. Schmidt,, M. Bitzan, and, H. Karch. 2000. Molecular characteristics and epidemiological significance of Shiga toxin-producing Escherichia coli O26 strains. J. Clin. Microbiol. 38:21342140.
136. Zhang, X.,, A. D. McDaniel,, L. E. Wolf,, G. T. Keusch,, M. K. Waldor, and, D. W. Acheson. 2000. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181:664670.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error